Premium
An unusually glycosylated form of acetylcholinesterase is a CSF biomarker for Alzheimer's disease
Author(s) -
SáezValero* J.,
Mok Ss S.,
Small D. H.
Publication year - 2000
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1034/j.1600-0404.2000.00307.x
Subject(s) - acetylcholinesterase , biomarker , cerebrospinal fluid , alzheimer's disease , aché , disease , glycosylation , medicine , abnormality , dementia , chemistry , enzyme , biochemistry , psychiatry
The identification of a biochemical marker of Alzheimer's disease (AD) is a major research aim of many groups. Abnormal levels of tau and Aβ have been identified in the cerebrospinal fluid (CSF) of AD patients, although the sensitivity and specificity of the changes in these two biomarkers alone is not sufficient to be of diagnostic value. Recently, our group has identified an abnormality in the glycosylation of acetylcholinesterase (AChE). The increase in this glycoform of AChE is very specific for Alzheimer's disease and is not seen in many other neurological diseases including other dementias.